Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Folprecht, Gunnar

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. [electronic resource] - The Lancet. Oncology Jan 2010 - 38-47 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

1474-5488

10.1016/S1470-2045(09)70330-4 doi


Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Austria
Camptothecin--adverse effects
Cetuximab
Chemotherapy, Adjuvant
Colorectal Neoplasms--pathology
ErbB Receptors--analysis
Female
Fluorouracil--adverse effects
Germany
Hepatectomy
Humans
Leucovorin--adverse effects
Linear Models
Liver Neoplasms--chemistry
Magnetic Resonance Imaging
Male
Middle Aged
Mutation
Neoadjuvant Therapy
Odds Ratio
Organoplatinum Compounds--adverse effects
Proto-Oncogene Proteins--genetics
Proto-Oncogene Proteins B-raf--genetics
Proto-Oncogene Proteins p21(ras)
Retrospective Studies
Risk Assessment
Time Factors
Tomography, Spiral Computed
Treatment Outcome
ras Proteins--genetics